Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533582 · ClinicalTrials.gov registry record · Phase 3
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
A Phase 3 study of Hepatoblastoma and Fibrolamellar Carcinoma, sponsored by Children's Oncology Group.
- Active
- Registry status
- Phase 3
- Development phase
- 537
- Enrollment target
- 20
- Study locations
NCT03533582 is a Phase 3 study of Hepatoblastoma and Fibrolamellar Carcinoma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 537 participants, above the 220-participant average among 9 other Hepatoblastoma trials with a reported enrollment target (144% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT03533582, a Phase 3 study of Hepatoblastoma and Fibrolamellar Carcinoma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 537 participants
- Enrollment target
- 20
- Study locations
Study Summary
This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy may kill more tumor cells than one type of chemotherapy alone.
Conditions Studied
Interventions
- DRUG Carboplatin
- PROCEDURE Biospecimen Collection
- DRUG Cisplatin
- DRUG Doxorubicin
- DRUG Etoposide
Study Locations (20)
California
- Kaiser Permanente Downey Medical Center - Downey
- Loma Linda University Medical Center - Loma Linda
- Miller Children's and Women's Hospital Long Beach - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Mattel Children's Hospital UCLA - Los Angeles
- Valley Children's Hospital - Madera
- UCSF Benioff Children's Hospital Oakland - Oakland
- Kaiser Permanente-Oakland - Oakland
- Children's Hospital of Orange County - Orange
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- Sutter Medical Center Sacramento - Sacramento
- University of California Davis Comprehensive Cancer Center - Sacramento
- Rady Children's Hospital - San Diego - San Diego
- Naval Medical Center -San Diego - San Diego
- UCSF Medical Center-Mission Bay - San Francisco
Arizona
- Banner Children's at Desert - Mesa
- Phoenix Childrens Hospital - Phoenix
Alabama
- Children's Hospital of Alabama - Birmingham
Alaska
- Providence Alaska Medical Center - Anchorage
Arkansas
- Arkansas Children's Hospital - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 537 participants |
| Start Date | 2018-05-24 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03533582
The ClinicalTrials.gov registry entry for NCT03533582 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 537 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 220-participant average among 9 other Hepatoblastoma trials with a reported enrollment target (144% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Hepatoblastoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03533582 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT03533582 about?
NCT03533582 is a clinical study titled "Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery". This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vi...
What is the current status of trial NCT03533582?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 537 participants. The study started on 2018-05-24. Estimated completion is 2026-12-31.
What conditions does trial NCT03533582 study?
This clinical trial studies the following conditions: Hepatoblastoma, Fibrolamellar Carcinoma, Childhood Malignant Liver Neoplasm, Childhood Hepatocellular Carcinoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified.
What interventions are being tested in trial NCT03533582?
The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Cisplatin (DRUG), Doxorubicin (DRUG), Etoposide (DRUG).
Who is sponsoring clinical trial NCT03533582?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03533582 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatoblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RECRUITING · Phase 1
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
RECRUITING · Phase 1
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.